154 related articles for article (PubMed ID: 32587951)
1. Characterization of RNA-Binding Motif 3 (RBM3) Protein Levels and Nuclear Architecture Changes in Aggressive and Recurrent Prostate Cancer.
Carleton NM; Zhu G; Miller MC; Davis C; Kulkarni P; Veltri RW
Cancer Rep (Hoboken); 2020 Jun; 3(3):e1237. PubMed ID: 32587951
[TBL] [Abstract][Full Text] [Related]
2. Nuclear Shape and Architecture in Benign Fields Predict Biochemical Recurrence in Prostate Cancer Patients Following Radical Prostatectomy: Preliminary Findings.
Lee G; Veltri RW; Zhu G; Ali S; Epstein JI; Madabhushi A
Eur Urol Focus; 2017 Oct; 3(4-5):457-466. PubMed ID: 28753763
[TBL] [Abstract][Full Text] [Related]
3. High RBM3 expression in prostate cancer independently predicts a reduced risk of biochemical recurrence and disease progression.
Jonsson L; Gaber A; Ulmert D; Uhlén M; Bjartell A; Jirström K
Diagn Pathol; 2011 Sep; 6():91. PubMed ID: 21955582
[TBL] [Abstract][Full Text] [Related]
4. PBOV1 as a potential biomarker for more advanced prostate cancer based on protein and digital histomorphometric analysis.
Carleton NM; Zhu G; Gorbounov M; Miller MC; Pienta KJ; Resar LMS; Veltri RW
Prostate; 2018 May; 78(7):547-559. PubMed ID: 29520928
[TBL] [Abstract][Full Text] [Related]
5. Quantitative alterations in nuclear structure predict prostate carcinoma distant metastasis and death in men with biochemical recurrence after radical prostatectomy.
Khan MA; Walsh PC; Miller MC; Bales WD; Epstein JI; Mangold LA; Partin AW; Veltri RW
Cancer; 2003 Dec; 98(12):2583-91. PubMed ID: 14669277
[TBL] [Abstract][Full Text] [Related]
6. High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions.
Grupp K; Wilking J; Prien K; Hube-Magg C; Sirma H; Simon R; Steurer S; Budäus L; Haese A; Izbicki J; Sauter G; Minner S; Schlomm T; Tsourlakis MC
Eur J Cancer; 2014 Mar; 50(4):852-61. PubMed ID: 24380696
[TBL] [Abstract][Full Text] [Related]
7. Prediction of prostate-specific antigen recurrence in men with long-term follow-up postprostatectomy using quantitative nuclear morphometry.
Veltri RW; Miller MC; Isharwal S; Marlow C; Makarov DV; Partin AW
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):102-10. PubMed ID: 18199716
[TBL] [Abstract][Full Text] [Related]
8. GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture.
Jeyapala R; Savio AJ; Olkhov-Mitsel E; Kamdar S; Zhao F; Cuizon C; Liu RSC; Zlotta A; Fleshner N; van der Kwast T; Bapat B
Eur Urol Oncol; 2019 May; 2(3):231-238. PubMed ID: 31200836
[TBL] [Abstract][Full Text] [Related]
9. Akt Activation Correlates with Snail Expression and Potentially Determines the Recurrence of Prostate Cancer in Patients at Stage T2 after a Radical Prostatectomy.
Chen WY; Hua KT; Lee WJ; Lin YW; Liu YN; Chen CL; Wen YC; Chien MH
Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27455254
[TBL] [Abstract][Full Text] [Related]
10. PPM1D as a novel biomarker for prostate cancer after radical prostatectomy.
Jiao L; Shen D; Liu G; Jia J; Geng J; Wang H; Sun Y
Anticancer Res; 2014 Jun; 34(6):2919-25. PubMed ID: 24922655
[TBL] [Abstract][Full Text] [Related]
11. Increased mediator complex subunit CDK19 expression associates with aggressive prostate cancer.
Becker F; Joerg V; Hupe MC; Roth D; Krupar R; Lubczyk V; Kuefer R; Sailer V; Duensing S; Kirfel J; Merseburger AS; Brägelmann J; Perner S; Offermann A
Int J Cancer; 2020 Jan; 146(2):577-588. PubMed ID: 31271443
[TBL] [Abstract][Full Text] [Related]
12. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.
Klein EA; Cooperberg MR; Magi-Galluzzi C; Simko JP; Falzarano SM; Maddala T; Chan JM; Li J; Cowan JE; Tsiatis AC; Cherbavaz DB; Pelham RJ; Tenggara-Hunter I; Baehner FL; Knezevic D; Febbo PG; Shak S; Kattan MW; Lee M; Carroll PR
Eur Urol; 2014 Sep; 66(3):550-60. PubMed ID: 24836057
[TBL] [Abstract][Full Text] [Related]
13. CD147 expression predicts biochemical recurrence after prostatectomy independent of histologic and pathologic features.
Bauman TM; Ewald JA; Huang W; Ricke WA
BMC Cancer; 2015 Jul; 15():549. PubMed ID: 26209327
[TBL] [Abstract][Full Text] [Related]
14. p300 (histone acetyltransferase) biomarker predicts prostate cancer biochemical recurrence and correlates with changes in epithelia nuclear size and shape.
Isharwal S; Miller MC; Marlow C; Makarov DV; Partin AW; Veltri RW
Prostate; 2008 Jul; 68(10):1097-104. PubMed ID: 18459105
[TBL] [Abstract][Full Text] [Related]
15. Prognostic accuracy of Prostate Health Index and urinary Prostate Cancer Antigen 3 in predicting pathologic features after radical prostatectomy.
Cantiello F; Russo GI; Ferro M; Cicione A; Cimino S; Favilla V; Perdonà S; Bottero D; Terracciano D; De Cobelli O; Morgia G; Damiano R
Urol Oncol; 2015 Apr; 33(4):163.e15-23. PubMed ID: 25575715
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy.
Geybels MS; Wright JL; Bibikova M; Klotzle B; Fan JB; Zhao S; Feng Z; Ostrander EA; Lin DW; Nelson PS; Stanford JL
Clin Epigenetics; 2016; 8():97. PubMed ID: 27651837
[TBL] [Abstract][Full Text] [Related]
17. A four-gene transcript score to predict metastatic-lethal progression in men treated for localized prostate cancer: Development and validation studies.
Cheng A; Zhao S; FitzGerald LM; Wright JL; Kolb S; Karnes RJ; Jenkins RB; Davicioni E; Ostrander EA; Feng Z; Fan JB; Dai JY; Stanford JL
Prostate; 2019 Oct; 79(14):1589-1596. PubMed ID: 31376183
[TBL] [Abstract][Full Text] [Related]
18. The Significance of Accurate Determination of Gleason Score for Therapeutic Options and Prognosis of Prostate Cancer.
Helpap B; Ringli D; Tonhauser J; Poser I; Breul J; Gevensleben H; Seifert HH
Pathol Oncol Res; 2016 Apr; 22(2):349-56. PubMed ID: 26563277
[TBL] [Abstract][Full Text] [Related]
19. Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer.
Jögi A; Brennan DJ; Rydén L; Magnusson K; Fernö M; Stål O; Borgquist S; Uhlen M; Landberg G; Påhlman S; Pontén F; Jirström K
Mod Pathol; 2009 Dec; 22(12):1564-74. PubMed ID: 19734850
[TBL] [Abstract][Full Text] [Related]
20. DNA Ploidy as surrogate for biopsy gleason score for preoperative organ versus nonorgan-confined prostate cancer prediction.
Isharwal S; Miller MC; Epstein JI; Mangold LA; Humphreys E; Partin AW; Veltri RW
Urology; 2009 May; 73(5):1092-7. PubMed ID: 19193410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
